Zilola Avazovna Olimova

2 ta ish

Ilboza medical, Tashkent, Uzbekistan

1. Is early inclusion of neratinib with HER blockers possible in the treatment of stage 4 HER2 positive cancer?

   Zilola Avazovna Olimova

   MaqolaHER2/EGFR in Cancer ResearchJournal of Clinical Oncology20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.007521

2. Abstract 2510: Comprehensive genomic profiling drives precision oncology and expands accessibility to targeted therapies in Uzbek populations

   Zilola Avazovna Olimova, Gowhar Shafi, D. Farrukh +10

   MaqolaCancer Genomics and DiagnosticsCancer Research20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.010172